Related Experiment Video
Updated: Feb 12, 2026

Generation of Organ-conditioned Media and Applications for Studying Organ-specific Influences on Breast Cancer Metastatic Behavior
Published on: June 13, 2016
Ex-vivo organ culture as potential prioritization tool for breast cancer targeted therapy
Albert Grinshpun1, Nancy Gavert2, Roy Zvi Granit3
1a Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center , Jerusalem , Israel.
Abstract:
The growing use of genomic testing presents new treatment options but also new dilemmas. We describe here a heavily-pretreated metastatic triple negative breast cancer patient who failed to respond to conventional treatment. Genomic analyses were performed that discovered several targetable alterations (e.g. FGFR1, CDK6, INSR) and created a clinical challenge - which target to target first? Our solution to this relatively common scenario was using ex-vivo organ culture (EVOC) system to prioritize treatment directed toward the best molecular target. EVOC enabled the trial of several potent targeted agents (Everolimus, Linsitinib, Palbociclib, AZD4547) and allowed semi-quantitative measurement of tumor response. The best response was to FGFR inhibitor, AZD4547. Consequently, the most accessible FGFR inhibiting agents (Pazopanib, then Nintedanib) were administered and some response was achieved. This report provides a potential rationale for utilizing EVOC system to predict tumor response to targeted therapy when multiple targets are proposed.
Insights
Genomic testing reveals multiple targets in metastatic breast cancer. Ex-vivo organ culture (EVOC) prioritized treatment, showing an FGFR inhibitor was most effective, guiding subsequent clinical therapy.
Area of Science:
- Oncology
- Genomics
- Personalized Medicine
Background:
- Metastatic triple-negative breast cancer (TNBC) presents treatment challenges, especially after failure of conventional therapies.
- Genomic profiling identifies multiple potentially targetable alterations (e.g., FGFR1, CDK6, INSR) in advanced TNBC, creating a clinical dilemma regarding optimal treatment sequencing.
Observation:
- A heavily pretreated metastatic TNBC patient with multiple identified molecular targets was treated.
- An ex-vivo organ culture (EVOC) system was employed to test the efficacy of various targeted agents against the patient's tumor.
Findings:
- EVOC testing revealed that the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 demonstrated the most significant tumor response.
- Clinical administration of FGFR inhibitors (Pazopanib, then Nintedanib) resulted in a partial therapeutic response.
Implications:
- Ex-vivo organ culture (EVOC) offers a predictive model for prioritizing targeted therapies when multiple molecular targets are identified in cancer.
- This approach may guide personalized treatment strategies for patients with advanced cancers, optimizing therapeutic selection and improving outcomes.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Gene Therapy
Potential Energy
Chemical bonds that form attractive forces between atoms also contain potential energy, called chemical energy. When a chemical reaction...
Levels of Organization
Molecules Are Composed of Atoms, and Biomolecules Are Assembled from Molecules:
The most basic levels include atoms, molecules, and biomolecules. Atoms, the smallest unit of ordinary matter, are composed of a nucleus and electrons. Molecules...
Accessory Organs

